Catalog No.
YHC43001
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Glu22-Arg153
Predicted molecular weight
17.26 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P09681
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Glucose-dependent insulinotropic polypeptide, Gastric inhibitory polypeptide, GIP, Incretin hormone
Uncovering Hidden Gluten Exposure in Celiac Patients: A Case Study in Family-Based Management and the Role of Point-of-Care Urine Testing and Psychological Assessment., PMID:40507945
Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes., PMID:40507203
Tirzepatide: a novel therapeutic approach for Alzheimer's disease., PMID:40498212
The evolution of the therapeutic concept 'GIP receptor antagonism'., PMID:40469445
Contractile effects of retatrutide in isolated mouse atrial preparations., PMID:40464942
[Nutritional management of type 2 diabetes with GLP-1 and GLP-1/GIP agonists]., PMID:40443143
Spexin is a biomarker of the process that regulates leptin sensitivity., PMID:40419220
Gut hormone secretion in a new meal tolerance test on insulin, glucagon, and glycemic excursions in patients with morbid obesity undergone sleeve gastrectomy., PMID:40418211
Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study., PMID:40412626
Bariatric Surgery and GLP-1/GIP Medications for the Treatment of Obstructive Sleep Apnoea: A Comprehensive Review., PMID:40407960
A combinatorial siRNA and mRNA approach for obesity treatment using targeting lipid nanoparticles., PMID:40383157
Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study., PMID:40368924
Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes., PMID:40368575
Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD., PMID:40364529
Postprandial Responses to Animal Products with Distinct Fatty Acid and Amino Acid Composition Are Diet-Dependent., PMID:40362890
Neuroprotective Potential of the Flavonoids Quercetin and Epicatechin in a C. elegans Tauopathy Model., PMID:40351085
GLP-1 receptor agonist properties of a chimeric peptide derived by hybridization of Latrodectus αLatrotoxin and Heloderma Exendin-4., PMID:40347985
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges., PMID:40344943
The long-term survival of enteroendocrine cells depends on their subtype and is linked to peripheral sensory innervation., PMID:40342092
A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist., PMID:40330819
Circulating Immune and Endocrine Markers in Currently Drinking and Abstinent Individuals With Alcohol Use Disorder and Controls., PMID:40317574
NDR2 kinase: A review of its physiological role and involvement in carcinogenesis., PMID:40311964
Glucose-dependent insulinotropic peptide and beyond: co-agonist innovations in the treatment of metabolic diseases., PMID:40306536
Effects of patient age on the therapeutic effects of GIP/GLP-1 receptor agonists (tirzepatide)., PMID:40301081
Tirzepatide increased force of contraction in the isolated human atrium., PMID:40299022
Early involvement of D-serine in β-amyloid-dependent pathophysiology., PMID:40293541
Calciprotein particle-activated endothelial cells aggravate smooth muscle cell calcification via paracrine signalling., PMID:40287595
Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes., PMID:40275332
GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series., PMID:40274278
The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions., PMID:40244362
[SURMOUNT-OSA study : tirzepatide improves obstructive sleep apnoea in patients with obesity]., PMID:40243250
Comparative efficacy of preloading plant-based versus animal-based proteins in evoking insulin and incretin responses to attenuate postprandial glucose., PMID:40237897
Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists., PMID:40237182
The effects of initiating a 24-hour fast with a low versus a high carbohydrate shake on glycemic control in older adults: a randomized crossover study., PMID:40234969
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study., PMID:40220739
Anionic Cyanine Membrane Probes for Live Cells and In Vivo Fluorescence Imaging., PMID:40217570
Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics., PMID:40216261
Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials., PMID:40212008
Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data., PMID:40210807
Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation., PMID:40203836
The C-terminal regions of the GLP-1 and GIP receptors are not the key determinants of their differential arrestin recruitment but modulate the rate of receptor endocytosis., PMID:40201698
On the front lines of cardiovascular-kidney-metabolic syndrome: Review of GLP-1 and Dual GLP-1/GIP receptor agonists in CV and kidney health., PMID:40197714
Effect of a Meal on Invasive Hemodynamics and Plasma Incretin Levels in Patients With Heart Failure., PMID:40190265
Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States., PMID:40181696
Apolipoproteins in ischemic stroke progression and recovery: Key molecular mechanisms and therapeutic potential., PMID:40180226
Identifying links between cardiovascular disease and insomnia by modeling genes from a pleiotropic locus., PMID:40176577
The role of GIPR in food intake control., PMID:40166681
Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study., PMID:40164173
Exploring Genetic Factors Associated with Moniezia spp. Tapeworm Resistance in Central Anatolian Merino Sheep via GWAS Approach., PMID:40150341
Growth inhibitory peptides: a potential novel therapeutic approach to cancer treatment., PMID:40147579
For research use only. Not for human or drug use.
